Last SFr.80.85 CHF
Change Today +0.55 / 0.68%
Volume 3.0M
NOVN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 11:31 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 11 11

Fax:

Novartis AG, through its subsidiaries, engages in researching, developing, manufacturing, and marketing a range of healthcare products led by pharmaceuticals worldwide. The company’s portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter (OTC), and animal health products. Divisions The company operates through five divisions: Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, and Consumer Health. PHARMACEUTICALS This division researches, develops, manufactures, distributes, and sells patented prescription medicines and is organized in various business franchises, including oncology; primary care, consisting of primary care medicines and established medicines; and specialty care, including ophthalmology, neuroscience, integrated hospital care, and critical care medicines. This division provides patent-protected medicines to patients and physicians. This division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis oncology, a business unit responsible for the global development and commercialization of oncology products. The product portfolio of this division includes approximately 50 primary marketed products. In addition, this division's portfolio of development projects includes 130 new products and new indications or new formulations for existing products in various stages of clinical development. Products Oncology Gleevec/Glivec (imatinib mesylate/imatinib mesylate) is a kinase inhibitor approved to treat patients with metastatic and/or unresectable KIT+ gastrointestinal stromal tumors (GIST), as an adjuvant treatment for certain adult patients following resection of KIT+ GIST, and as a targeted therapy for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Gleevec/Glivec is available in approximately 110 countries. Gleevec/Glivec is also approved in the United States (U.S.), the European Union (EU), and Japan to treat Philadelphia chromosome-positive acute lymphoblastic leukemia, a rapidly progressive form of leukemia. Gleevec/Glivec is also approved in the U.S. and the EU to treat dermatofibrosarcoma protuberans, a rare solid tumor; hypereosinophilic syndrome and myelodysplastic/myeloproliferative diseases; and other rare blood disorders. In the U.S., Gleevec is approved for aggressive systemic mastocytosis. Gleevec/Glivec has received approvals as a post-surgery (adjuvant setting) therapy for certain KIT+ GIST patients in approximately 60 countries, including the U.S. and the EU. Sandostatin SC/Sandostatin LAR (octreotide acetate/octreotide acetate for injectable suspension) is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Additionally, Sandostatin LAR is approved in 44 countries for the delay of tumor progression in patients with midgut carcinoid tumors. A total of 40 countries have also approved a new presentation of Sandostatin LAR, which includes a new diluent, safety needle and vial adapter improving the mixing and administration, with additional filings underway. Afinitor/Votubia (everolimus), is an oral inhibitor of the mTOR pathway: Afinitor is approved in approximately 100 countries and regions including the U.S., EU member states and Japan for advanced renal cell carcinoma following vascular endothelial growth factor-targeted therapy. Afinitor is also approved in approximately 50 countries, including the U.S., EU and Japan for the treatment of advanced pancreatic neuroendocrine tumors. In addition, Afinitor is approved in approximately 75 countries for advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+/HER2- breast cancer). Everolimus is also approved in approximately 40 countries including in the U.S. as Afinitor and in the EU as Votubia to treat patients with subependymal giant cell astrocytoma (SEGA) associa

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.80.85 CHF +0.55

NOVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $101.70 USD +0.4201
Merck & Co Inc $59.39 USD +0.48
Roche Holding AG SFr.265.50 CHF +0.10
Sanofi €79.28 EUR -0.47
Procter & Gamble Co/The $82.85 USD +0.1572
View Industry Companies
 

Industry Analysis

NOVN

Industry Average

Valuation NOVN Industry Range
Price/Earnings 23.7x
Price/Sales 3.6x
Price/Book 3.0x
Price/Cash Flow 24.5x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.